Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic vs Brand Name Travoprost in Glaucoma/OHT
NCT02796560Phase 4Completed
- Sponsor
- Université de Sherbrooke
- Start
- Jul 2016
- Primary completion
- Sep 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of travoprost in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Université de Sherbrooke. Primary endpoint: Intraocular Pressure at 3 weeks. Started Jul 2016; status: completed.
02
Drugs
travoprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02796560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796560.